Greenwich LifeSciences, Inc. — FY2020 Form 10-K
Reporting period: Year ended December 31, 2020; filed March 31, 2021. The filing does not provide separate fourth-quarter results. Greenwich is a clinical-stage biopharmaceutical company developing GP2, an immunotherapy intended to prevent breast cancer recurrence after surgery. It had no product revenue.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.06 million | $2.61 million |
| General and administrative expense | $806,188 | $818,887 |
| Net loss | $1.86 million | $3.43 million |
| Net loss per share, basic and diluted | $0.20 | $1.52 |
| Cash used in operating activities | $1.15 million | $293,267 |
| Cash at year-end | $28.66 million | $6,835 |
Research and development expense fell 59%, primarily because of lower compensation costs; G&A was nearly unchanged. Net loss narrowed year over year. No operating margin is meaningful because the company had no revenue. The filing reports no investing cash flows in either year.
Financing activities provided $29.81 million in 2020, including net proceeds of $6.21 million from the September IPO and $23.96 million from the December follow-on offering; the company repaid $360,000 of related-party loans. Year-end total liabilities were $1.05 million, including $275,154 due to related parties and $710,971 in accounts payable and accrued interest. Stockholders’ equity was $27.63 million; accumulated deficit was $29.08 million.
Management said year-end cash was expected to fund operating and capital needs for at least 12 months from the filing date, but substantial additional capital is required to develop GP2. The notes state that the 2020 offerings mitigated substantial doubt about the company’s ability to continue as a going concern for the following 12 months. Phase III costs were estimated at $12–15 million through an interim analysis, potentially over $16 million through an interim analysis and BLA filing, and over $30 million to complete the trial as planned.
Development, outlook, and material risks
- GP2 evidence: The company reported a Phase IIb median five-year disease-free survival estimate of 100% for 46 HER2 3+ patients who completed the six-injection primary series, versus 89.4% for 50 placebo patients; reported p=0.0338. In the HER2 1–2+ completer subgroup, reported rates were 77.1% versus 77.6% (p=0.9142). These are subgroup/per-protocol results; the filing also describes 180 intent-to-treat patients and 168 who completed the primary series. The filing’s descriptions of final analysis status are not entirely consistent.
- Safety: The company reported no serious adverse events in the GP2 trials involving 138 recipients; reported effects were mainly injection-site reactions and mild systemic symptoms. The filing cautions that existing studies may not detect rare or delayed adverse events.
- Phase III plan: The company planned to begin a Phase III trial in 2021. FDA had reviewed the manufacturing plan and protocol; protocol revisions, including possible interim analysis/adaptive design, were still underway. The company anticipated up to two years for enrollment and potentially median five-year follow-up, while stating interim analysis might shorten reporting and BLA timing. GP2 manufacturing had commenced; CRO and CMO engagements were being finalized.
- Key execution and financing risks: GP2 has no regulatory approval, and Phase II results do not assure Phase III success. The company depends on third parties for trials and manufacturing, including a single GM-CSF supplier without a supply agreement. It had only one full-time and two part-time employees as of March 2021, no commercial infrastructure, and no committed additional capital source. Financing may dilute shareholders or require unfavorable licensing or strategic terms.
- Other risks and contingencies: COVID-19 could disrupt enrollment, trial sites, supply, regulatory review, and access to financing. Intellectual-property protection depends on an exclusive HJF license; licensed patents were reported to expire from 2026 to 2032. The company reported no material pending legal proceedings and no off-balance-sheet arrangements. A potential coronavirus-vaccine program was subject to an option agreement with Westport Bio, involving up to $250,000 of sponsored research plus additional fees; the counterparty’s founder is the CEO.
- Controls and unusual items: Management concluded disclosure controls were ineffective at December 31, 2020 because of material weaknesses, including inadequate segregation of duties and insufficient written accounting, IT, and financial-reporting procedures. Management was developing remediation plans. The independent auditor gave an unqualified opinion on the financial statements but was not engaged to audit internal-control effectiveness. The company also disclosed that related-party loans were subsequently paid off by March 15, 2021, and that the underwriter exercised an option in January 2021 for additional shares, generating $2.55 million net proceeds.
Important facts for investors to verify
- Reconcile the Phase IIb trial’s final analysis status, intent-to-treat versus completer populations, subgroup results, and interpretation of the reported efficacy statistics.
- Check whether the planned Phase III trial actually began, its finalized design and enrollment targets, and the timing and conditions of any interim analysis.
- Compare actual cash burn and trial commitments with the stated cash runway and estimated Phase III funding requirements; assess the need for further financing and dilution.
- Confirm manufacturing readiness, CRO/CMO contracts, GM-CSF supply continuity, and any required regulatory approvals or protocol changes.
- Track remediation of the material weaknesses in internal controls and any subsequent auditor or management assessments.